Sickle Cell Drug Oxbryta Faces Lawsuit After Market Withdrawal

Patient Lawsuit Highlights Risks of Recently Discontinued Sickle Cell Drug

A lawsuit filed in California alleges that the recently discontinued sickle cell drug Oxbryta caused severe adverse health effects. Plaintiff Tirrell Allen, who had taken the drug for just over a month, experienced severe swelling, pain, and an increase in vaso-occlusive crises. His condition escalated to a stroke in September, leaving him hospitalized. The lawsuit accuses Pfizer, Oxbryta’s manufacturer, of failing to adequately warn patients about the drug’s risks, even as post-market clinical trials revealed troubling data.

5 Key Points

• Oxbryta was voluntarily removed from the market in 2024 after post-market trials showed increased risks.

• Plaintiff Tirrell Allen claims the drug caused severe symptoms, including a stroke.

• Clinical trials linked Oxbryta to higher rates of vaso-occlusive crises and deaths compared to a placebo.

• The FDA approved Oxbryta through its accelerated pathway in 2019 to address unmet medical needs.

• Pfizer advised patients to seek alternative treatments as the safety review continues.

Plaintiff Details Severe Health Effects Following Oxbryta Use

Tirrell Allen, a California resident who has lived with sickle cell disease for most of his life, began taking Oxbryta in August 2024. Within weeks, he experienced swelling, pain, and an increase in vaso-occlusive crises. These episodes, which are common in sickle cell patients, occur when sickled red blood cells block blood flow, causing severe pain. In September, Allen suffered a stroke attributed to the drug, resulting in a prolonged hospital stay. His lawsuit, filed in early November, claims Pfizer did not properly warn patients about the drug’s risks. At the time of the filing, Allen remained hospitalized due to his condition.

Understanding Sickle Cell Disease and Its Challenges

Sickle cell disease is a genetic blood disorder that affects hemoglobin, the molecule in red blood cells responsible for carrying oxygen. In individuals with this condition, red blood cells become rigid and crescent-shaped, impairing their ability to flow smoothly through blood vessels. These sickled cells can block blood flow, leading to episodes of severe pain, organ damage, and an increased risk of infections. Common complications include anemia, strokes, and chronic fatigue. The disease disproportionately affects individuals of African descent but also occurs in people from Mediterranean, Middle Eastern, and South Asian backgrounds. Treatment for sickle cell disease typically includes methods like pain management, blood transfusions, and medications such as hydroxyurea, which is used to manage some complications of the disease.

Get a free legal case review today

Did you develop any of the following injuries after being exposed to Fire Fighting Foam (AFFF)? * Choose one Ulcerative Colitis Kidney Cancer Pancreatic Cancer Testicular Cancer Prostate Cancer Bladder Cancer Thyroid Disease Liver Cancer Non-Hodgkin's Lymphoma None of the above Were you exposed to Fire Fighting Foam (AFFF)? *

YesNo

Which medication(s) did you take during your pregnancy? * Choose one Tylenol Acetaminophen Alka-Seltzer Coricidin Dayquil Excedrin FluTherapy Midol Mucinex Nyquil Panadol Robitussin Sinex Sudafed Theraflu Other Medication(s) Was your child diagnosed with Autism, ADHD or another condition? * Choose one Autism/Autism Spectrum Disorder (ASD) Attention Deficit Hyperactivity Disorder (ADHD) Asperger’s Syndrome Kanner’s Syndrome Childhood Disintegrative Disorder Pervasive Developmental Disorder Other Medical Condition How old was your child at the time of diagnosis? *

Under 18 years old18+ years old

Did the accident occur within the last 2 years? *

YesNo

First Name *

Last Name *

Email Address *

ZIP Code *

Phone Number *

What is your case type? * Choose one -------------------- Asbestos Baby Formula Camp Lejeune Clergy Abuse CPAP Elmiron Exactech Firefighting Foam FTX Exchange Hair Relaxer Hernia Mesh Paraquat PFAS Roundup Sex Abuse Social Media Talcum Powder Tepezza Tylenol -------------------- Birth Injury Car Accident FELA Medical Malpractice Motorcycle Accident Slip and Fall Trucking Accident Uber & Lyft Rideshare Workplace Injury Weight Loss Wrongful Death -------------------- Something Else

Human Verification *

I understand and agree that (a) submitting this form does not create an attorney-client relationship, (b) I am not already represented by an attorney for this matter, (c) the information I submit will be shared with a law firm, and (d) I have read and accepted the terms and conditions of the Privacy Policy, Terms of Service and Legal Disclaimer. Further, I consent to being contacted by a law firm or its agent after submitting this request.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Pfizer’s Withdrawal of Oxbryta Sparks Safety Concerns

Pfizer voluntarily withdrew Oxbryta from the market in October 2024, citing alarming findings from post-market clinical trials. According to a company statement, “Pfizer’s decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.” The trials revealed higher rates of vaso-occlusive crises and deaths among Oxbryta users compared to those receiving a placebo. Chief Medical Officer Aida Habtezion highlighted that patient safety was the top priority, advising individuals to “contact their physicians to discuss alternative treatment while we continue to investigate the findings.”

FDA Reviews Accelerated Approval Process Amid Controversy

Oxbryta received FDA approval in 2019 through the agency’s accelerated pathway, designed to address unmet medical needs for serious conditions. The drug was later approved for younger children under the same program. While the process allows for quicker access to potentially life-saving treatments, it has faced criticism for not requiring longer-term safety studies. The FDA has stated it will release more findings after completing its review of Oxbryta’s clinical trial data.

Sickle Cell Patients Seek Answers After Oxbryta’s Withdrawal

Oxbryta’s removal has left many sickle cell patients seeking alternative therapies. The drug was marketed as a breakthrough treatment for sickle cell disease, a condition with limited options and significant health challenges. Patients like Allen, who hoped for relief from the drug, instead faced severe complications. Lawsuits against Pfizer are now raising questions about whether patients were adequately informed of the risks. The situation raises concerns about balancing quick drug approvals with thorough safety testing, ensuring that new treatments are both effective and safe for those who need them most.